CompletedNot Applicable

Peer Education as a Strategy to Promote Vaccine Acceptance

United States154 participantsStarted 2022-03-06

Plain-language summary

Effective interventions to improve uptake of vaccines among hesitant groups are urgently needed. Peer education is an effective intervention in modifying health behaviors in other conditions and may be effective in promoting vaccine confidence but has not been studied. To fill this knowledge gap, we will enroll approximately 152 parents of children age 0-18 months who are eligible for pneumococcal conjugate (PCV-13) vaccine and randomize them 1:1 to a peer-led vaccine education intervention or usual care.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. A parent of a child aged 0 to 18 months born at ≥35 weeks' gestation who is eligible for a dose of PCV-13. Eligibility by age defined as follows:
✓. Age 0-6 months: never received first dose or is \>8 weeks from last dose (3 doses scheduled in this age group at 2, 4, and 6 months)
✓. Age 7-11 months: never received first dose or is \> 8 weeks from last dose (2 doses scheduled in this age group if started at 7 months)
✓. 12-18 months: never received first dose, is \>8 weeks from last dose (2 doses scheduled in this age group if started at 12 months) or is due for booster at 12-18 months having received primary series between age 2-11 months.
✓. Self-identifies as Orthodox Jewish.
✓. Is able to provide informed consent.

Exclusion criteria

✕. Unable to communicate verbally in English or Yiddish
✕. Unwilling or unable to utilize a Yiddish in-person or telephone interpreter
✕. Has already participated in this study as an eligible adult or parent. A parent will only be able to participate in this study once (i.e. for only one child in the family that is eligible)
✕. Has an appointment at clinic that day to specifically receive vaccines.

What they're measuring

Number of Participants Ages 0 Months to 18 Months at Enrollment who Receive at least One Dose of PCV-13 Vaccine by 3 Months Post-Enrollment

Timeframe: Month 3 Post-Enrollment

Trial details

NCT IDNCT05875779

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-27

View on ClinicalTrials.gov More Vaccine Acceptance trials